Follow The Filings

AZN AstraZeneca

AstraZeneca earnings company data as of 2:06 PM ET 10/30

  • 1 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 30 Oct EPS 2.16 — —
Rev $16.00B — —
FY2026 Q2 27 Jul EPS 2.50 2.63 Beat +5.2%
Rev — — —

Which managers own it 13F portfolio weights, not free-float

Insider trades

Open-market buys and sales by AZN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AZN insider trades
  • $3,249 bought by 1 insider
  • $2.2M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Mani Sharma See Remarks
    Buy
    $3,249 20 shares at $160.57 +0.1% to stake
    Traded Aug 8 Filed Sep 11
    ↗
  2. Mani Sharma See Remarks
    Sale
    $2.2M 11,893 shares at $185.78 38% of stake
    Traded May 20 Filed May 22
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
6-K 3RD QUARTER RESULTS Filing Doc
6-K ENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC Filing Doc
6-K ULTOMIRIS APPROVED IN US IN IGAN Filing Doc
6-K ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT Filing Doc
6-K AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K ADMISSION OF FURTHER SECURITIES TO TRADING Filing Doc
6-K ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT Filing Doc
6-K TRIXEO APPROVED IN EU FOR ASTHMA Filing Doc
6-K KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP Filing Doc
6-K ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K DIRECTOR/PDMR SHAREHOLDING Filing Doc
6-K UPDATE ON SERENA-4 PHASE III TRIAL Filing Doc
6-K IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG Filing Doc
6-K ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER Filing Doc
6-K TOTAL VOTING RIGHTS Filing Doc
6-K ADMISSION OF FURTHER SECURITIES TO TRADING Filing Doc
6-K TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG Filing Doc
6-K ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY Filing Doc
6-K DIRECTORATE CHANGE Filing Doc
6-K ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC Filing Doc
6-K ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING Filing Doc
6-K TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS Filing Doc

Source: SEC EDGAR submissions, updated about 7 hours ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.